为解决皮肤 T 细胞淋巴瘤（CTCL）治疗难题，研究人员探究 CD38 作用及联合疗法，发现联合治疗可提升疗效。 皮肤 T 细胞淋巴瘤（Cutaneous T-Cell Lymphoma，CTCL）是一种让人头疼的非霍奇金淋巴瘤，它专门 “攻击” 皮肤里的恶性 T 细胞。得了这种病，患者皮肤状况 ...

A new research paper was published in Oncotarget, Volume 16, on March 21, 2025, titled “NSD2-epigenomic reprogramming and ...

Our findings suggest a role for NSD2 in maintaining MM cell identity, with potential implications for future therapeutic ...

Despite initial clinical data showing efficacy, Genmab has decided to discontinue further clinical development of ...

A new research paper was published in Oncotarget , Volume 16, on March 21, 2025, titled "NSD2-epigenomic reprogramming and maintenance of plasma cell phenotype in t(4;14) myeloma." Researchers Andrea ...

Despite initial clinical data showing efficacy, Genmab has decided to discontinue further clinical development of HexaBody-CD38. “While we are disappointed that J&J has decided not to advance ...

Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter company to discontinue development of the program. Back in 2019 ...

While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a thorough evaluation of the data, the market landscape, and Genmab’s rigorous portfolio ...